Is Fusion Antibodies the one-stop shop for Humanizing Antibodies?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Is Fusion Antibodies the one-stop shop for Humanizing Antibodies?
Released on: September 26, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Fusion Antibodies is a Contract Research Organisation (CRO) established in 2001.
  • Summary
  • Transcript
  • Participants
  • Company
Fusion Antibodies is a Contract Research Organisation (CRO) established in 2001. Offering a fee-for-service, royalty free, risk free development service from discovery right through to clinical studies in areas such as, antigen expression and purification, antibody production and sequencing, right through to humanization, cGMP-ready stable cell lines and supply of material for clinical trials. Adrian Dawkes talks to the Managing Director Paul Kerr about the companies technological innovations.
Fusion Antibodies is a Contract Research Organisation (CRO) established in 2001. Offering a fee-for-service, royalty free, risk free development service from discovery right through to clinical studies in areas such as, antigen expression and purification, antibody production and sequencing, right through to humanization, cGMP-ready stable cell lines and supply of material for clinical trials. Adrian Dawkes talks to the Managing Director Paul Kerr about the companies technological innovations.
Paul Kerr: With more than 20 years experience in Bioscience and with over 13 years in Fusion Antibodies Ltd in a variety of technical roles, then 10 years in Business Development charged with developing the Contract Research services and seeking partners for the drug assets discovered and validated before joining the board and taking up the Managing Director role in 2011.
Fusion Antibodies is a Contract Research Organisation (CRO) established in 2001 as a spin-out from Queen’s University Belfast and located about 6 miles outside Belfast city centre. With 15+ years of experience in the medical research industry, including two of our own antibodies in clinical and pre-clinical trials, Fusion Antibodies is your first choice for accelerating your research towards the clinic. Fusion Antibodies Ltd OfficeFusion Antibodies started primarily working with E. coli expression systems and has won a host of awards for its E. coli technology platform - FET (Fusion Expression Technology) which accelerates the validation of targets from DNA sequence through to recombinant protein expression. We have since developed and expanded to provide a range of world class services in antibody development, production, characterization and optimization. Our services now range from antigen expression and purification, followed by antibody production and sequencing, right through to humanization, cGMP-ready stable cell lines and supply of material for clinical trials. At Fusion Antibodies we can provide project management and offer a fee-for-service, royalty free, risk free development service from discovery right through to clinical studies. Although we specialise in antibodies, Fusion Antibodies have produced cell lines and proteins for a wide variety of clinical applications. Our approach allows the client company to focus on the design and execution of their programs and for Fusion Antibodies to provide the materials. We will work closely with your team in a collaborative effort to get the best possible results. Fusion Antibodies, along with their cGMP partners Celonic AG, can offer a complete development pathway from ideas, to genes, to proteins, to antibodies and to the clinic.